JP2019535737A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535737A5 JP2019535737A5 JP2019527238A JP2019527238A JP2019535737A5 JP 2019535737 A5 JP2019535737 A5 JP 2019535737A5 JP 2019527238 A JP2019527238 A JP 2019527238A JP 2019527238 A JP2019527238 A JP 2019527238A JP 2019535737 A5 JP2019535737 A5 JP 2019535737A5
- Authority
- JP
- Japan
- Prior art keywords
- days
- treatment
- administered
- weeks
- medicament according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 35
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 claims description 9
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 claims description 9
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 claims description 4
- 210000000130 stem cell Anatomy 0.000 claims description 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims 80
- 229960003087 tioguanine Drugs 0.000 claims 40
- 239000003814 drug Substances 0.000 claims 21
- 229940079593 drug Drugs 0.000 claims 8
- 238000002054 transplantation Methods 0.000 claims 5
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 claims 1
- 230000002596 correlated effect Effects 0.000 claims 1
- 238000011476 stem cell transplantation Methods 0.000 description 6
- 230000003750 conditioning effect Effects 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 206010065553 Bone marrow failure Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 101000799388 Homo sapiens Thiopurine S-methyltransferase Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100034162 Thiopurine S-methyltransferase Human genes 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022192549A JP2023025149A (ja) | 2016-11-18 | 2022-12-01 | 低用量チオグアニンによるインビボ化学選択 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662423794P | 2016-11-18 | 2016-11-18 | |
| US62/423,794 | 2016-11-18 | ||
| PCT/US2017/062127 WO2018094126A1 (en) | 2016-11-18 | 2017-11-17 | In vivo chemoselection with low dose thioguanine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022192549A Division JP2023025149A (ja) | 2016-11-18 | 2022-12-01 | 低用量チオグアニンによるインビボ化学選択 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019535737A JP2019535737A (ja) | 2019-12-12 |
| JP2019535737A5 true JP2019535737A5 (enExample) | 2020-12-24 |
Family
ID=60915599
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019527238A Pending JP2019535737A (ja) | 2016-11-18 | 2017-11-17 | 低用量チオグアニンによるインビボ化学選択 |
| JP2022192549A Pending JP2023025149A (ja) | 2016-11-18 | 2022-12-01 | 低用量チオグアニンによるインビボ化学選択 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022192549A Pending JP2023025149A (ja) | 2016-11-18 | 2022-12-01 | 低用量チオグアニンによるインビボ化学選択 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20180140606A1 (enExample) |
| EP (1) | EP3541392A1 (enExample) |
| JP (2) | JP2019535737A (enExample) |
| KR (1) | KR20190086497A (enExample) |
| CN (1) | CN109963566A (enExample) |
| AU (1) | AU2017363154A1 (enExample) |
| CA (1) | CA3041531A1 (enExample) |
| WO (1) | WO2018094126A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4190339B1 (en) * | 2017-07-18 | 2025-07-02 | CSL Behring Gene Therapy, Inc. | A modulatable switch for selection of donor modified cells |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3384912B1 (en) * | 2011-04-20 | 2020-11-11 | The Regents of The University of California | Method for combined conditioning and chemoselection in a single cycle |
-
2017
- 2017-11-16 US US15/815,693 patent/US20180140606A1/en not_active Abandoned
- 2017-11-17 CN CN201780071180.4A patent/CN109963566A/zh active Pending
- 2017-11-17 JP JP2019527238A patent/JP2019535737A/ja active Pending
- 2017-11-17 EP EP17823250.0A patent/EP3541392A1/en not_active Withdrawn
- 2017-11-17 KR KR1020197017017A patent/KR20190086497A/ko not_active Ceased
- 2017-11-17 WO PCT/US2017/062127 patent/WO2018094126A1/en not_active Ceased
- 2017-11-17 AU AU2017363154A patent/AU2017363154A1/en not_active Abandoned
- 2017-11-17 CA CA3041531A patent/CA3041531A1/en active Pending
-
2019
- 2019-05-14 US US16/411,830 patent/US20190269687A1/en not_active Abandoned
-
2022
- 2022-12-01 JP JP2022192549A patent/JP2023025149A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Arora et al. | Pulsatile drug delivery systems: An approach for controlled drug delivery | |
| Surmeier | Calcium, ageing, and neuronal vulnerability in Parkinson's disease | |
| US20230172862A1 (en) | Extended release pharmaceutical compositions of levetiracetam | |
| WO2012072505A1 (en) | Volasertib alone or in combination with cytarabine for treating acute myeloid leukemia | |
| EP2827858B1 (en) | Administration of an antitumor agent | |
| RU2611396C2 (ru) | Способ совместного кондиционирования и хемоселекции за один цикл | |
| JP2019199476A5 (enExample) | ||
| ES2244968T3 (es) | Reduccion del volumen de infarto usando citocolina. | |
| JP2016029111A (ja) | ナルトレキソンの徐放型配合物 | |
| JP2010538066A5 (enExample) | ||
| CA2570474A1 (en) | A combination composition comprising paracetamol and ibuprofen | |
| JP2019535737A5 (enExample) | ||
| McElroy et al. | Randomized, double-blind, placebo-controlled study of divalproex extended release loading monotherapy in ambulatory bipolar spectrum disorder patients with moderate-to-severe hypomania or mild mania | |
| KR20190089005A (ko) | 에베롤리무스, 닥톨리십 또는 둘 다를 사용하여 면역 반응을 증진시키는 방법 | |
| KR20180058659A (ko) | 에베롤리무스와 닥톨리십의 약제학적 병용물 | |
| CA2672716C (fr) | Nouvelle utilisation therapeutique pour le traitement des leucemies | |
| JP2023025149A (ja) | 低用量チオグアニンによるインビボ化学選択 | |
| CN107823214A (zh) | 治疗免疫炎性疾病的组合物 | |
| FI3298042T3 (fi) | B-solujen vähentyminen diagnostisena merkkinä | |
| EP3795155A1 (en) | Pharmaceutical composition, comprising rhodanine derivative, for prevention or treatment of aids | |
| HUE030811T2 (hu) | Netupitant és palonosetron terápiás kombinációi | |
| Ackerman | Evaluation of three methods for determining initial vancomycin doses | |
| Bhavnani et al. | Pharmacokinetic-Pharmacodynamic Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex Lung Disease | |
| CA2912743A1 (en) | Combination of ro5503781, capecitabine and oxaliplantin for cancer therapy | |
| Scheggi et al. | Effects of the 5-HT6 receptor agonist ST 1936 on depression-and anhedonia-like experimental models |